Fulgent Genetics Inc. Common Stock
FLGTUnited States
5 filed reports · 319 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 1,324 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 1,022 | Dec 2025 |
Financial data
319 concepts · 2,346 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial309 concepts · 2,070 facts · Dec 2023 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest14 · Dec 2023 to Jun 2026
- Adjustments related to tax withholding for share based compensation13 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash and cash equivalents at carrying value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Other comprehensive income loss net of tax13 · Dec 2023 to Jun 2026
- Profit loss13 · Dec 2023 to Jun 2026
- Stock repurchased during period value13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax attributable to noncontrolling interest12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest12 · Dec 2023 to Jun 2026
- Contract with customer liability revenue recognized12 · Dec 2023 to Jun 2026
- Cost of revenue (US GAAP)12 · Dec 2023 to Jun 2026
- Defined contribution plan employer discretionary contribution amount12 · Dec 2023 to Jun 2026
- Depreciation12 · Dec 2023 to Jun 2026
- Fair value assets, transfers between levels, amount12 · Dec 2023 to Jun 2026
- Finance lease interest expense12 · Dec 2023 to Jun 2026
- Finance lease right of use asset amortization12 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
Segment9 concepts · 228 facts · Dec 2023 to Jun 2026
- Revenue78 · Dec 2023 to Jun 2026
- Cost of revenue (US GAAP)24 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization24 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)24 · Dec 2023 to Jun 2026
- Operating income loss24 · Dec 2023 to Jun 2026
- Research and development expense24 · Dec 2023 to Jun 2026
- Selling and marketing expense (US GAAP)24 · Dec 2023 to Jun 2026
- Goodwill acquired during period4 · Dec 2025 to Jun 2026
- Goodwill purchase accounting adjustments2 · Mar 2026 to Jun 2026
Geography1 concepts · 48 facts · Dec 2023 to Jun 2026
- Revenue48 · Dec 2023 to Jun 2026
Segments
276 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 174 facts
- Therapeutic Development88 · Dec 2023 to Jun 2026
- Laboratory Services86 · Dec 2023 to Jun 2026
Subsegments5 members · 54 facts
- Biopharma Services19 · Dec 2023 to Jun 2026
- Anatomic Pathology12 · Dec 2023 to Jun 2026
- Precision Diagnostics12 · Dec 2023 to Jun 2026
- Covid199 · Dec 2023 to Dec 2025
- Other Revenue2 · Sep 2024 to Sep 2025
Statement geographical4 members · 48 facts
- CN12 · Dec 2023 to Jun 2026
- Non Us12 · Dec 2023 to Jun 2026
- Other Countries12 · Dec 2023 to Jun 2026
- US12 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
- FY2026 Q1May 1, 2026
- FY2025 Q4Feb 27, 2026
- FY2025 Q3Nov 7, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.